The tool resolves a longstanding challenge in genetics by demonstrating how identical DNA sequences trigger varying disease risks depending on which specific genes different cell types activate. DeepMind trained the platform on over 100 million individual cell profiles across 68 tissues, allowing it to evaluate novel cellular states without requiring retraining. However, the system's demanding computational footprint means it will coexist with DeepMind's previous model rather than fully replace it. Google is opening access via an API for non-commercial researchers alongside a restricted commercial preview.
Key points
Researchers can deploy the system to evaluate previously unseen cell types and identify m…: Researchers can deploy the system to evaluate previously unseen cell types and identify missing experimental data without additional retraining.
Scientists aim to leverage the model's granular cellular insights to discover root diseas…: Scientists aim to leverage the model's granular cellular insights to discover root disease mechanisms and streamline targeted drug development.
Non-commercial investigators can access the model via an API, while private commercial pa…: Non-commercial investigators can access the model via an API, while private commercial partners receive limited preview access.
Sources checked by our analysis pipeline: 1
Researchers at Google DeepMind have unveiled a new AI model designed to unravel how changes in our DNA affect different cells, giving scientists a more detailed view of a notoriously difficult problem that could hold important clues to the causes of disease — and point the way to new treatments.
Google’s AlphaGenome 2 zooms in on the cellular roots of disease
DeepMind’s new DNA model better predicts how mutations affect different cells, potentially opening paths to treatment.
DeepMind’s new DNA model better predicts how mutations affect different cells, potentially opening paths to treatment.
AlphaGenome 2 is the successor to DeepMind’s genome-predicting AI model AlphaGenome, which was released last year. While nearly every cell in the human body carries the same DNA, different types of cells — from heart muscle cells and skin cells to immune cells fighting an infection — switch different genes on and off, and those patterns can change depending on what a cell is doing. As a result, the same genetic variant can have very different effects depending on the type and state of the cell.
The cross-border startup is targeting the growing enterprise ecosystem by designing specialized analytics infrastructure tailored to autonomous digital software. This substantial launch capital allows the team to scale development across its dual headquarters in Israel and California. The move signals heightened investor appetite for back-end data architectures built expressly to serve next-generation artificial intelligence workflows.
Healthcare technology developers are increasingly pushing to ingest extensive patient records and administrative files to power broader clinical recommendations. This rapid transition from narrow, single-purpose functions to wide-ranging medical decision support challenges traditional clinical perspectives on data limitation. The shift marks an aggressive effort by digital health platforms to expand their operational footprints across patient care.
To accelerate therapeutic development, Anthropic has forged partnerships with pharmaceutical companies and biotechs like Bristol Myers Squibb and BigHat Biosciences. The initiatives leverage the company's Claude AI models to engineer treatments for rare diseases, food allergies, and various forms of cancer. While laboratory tests show promise in optimizing drug molecules, the technologies remain strictly in preclinical development phases.